CARVYKTI (ciltacabtagene autoleucel) A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
CARVYKTI (ciltacabtagene autoleucel) A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
